Bimzelx 320 mg, 2 mL single-injection option now available for multiple indications
Click Here to Manage Email Alerts
Key takeaways:
- The new Bimzelx administration and dosage is available for multiple indications.
- It is recommended for plaque psoriasis, active psoriatic arthritis with coexistent plaque psoriasis and hidradenitis suppurativa.
The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available, UCB announced in a press release.
In addition to the already available 1 mL device containing 160 mg of Bimzelx (bimekizumab-bkzx), the company has now made the 2 mL prefilled syringe with 320 mg of Bimzelx available for the treatment of patients with moderate to severe plaque psoriasis, active psoriatic arthritis with coexistent moderate to severe plaque psoriasis and moderate to severe hidradenitis suppurativa.
“With five new FDA-approved indications for Bimzelx in just over a year, we’ve had the opportunity to reach a wider range of people living with chronic inflammatory conditions who have long been in need of new treatment options,” Camille Lee, head of U.S. Immunology at UCB, said in the press release.
The new single-injection dosage was approved on Oct. 14, 2024, based on studies that evaluated the bioequivalence of the drug’s 320 mg dose given as a 2 mL subcutaneous injection vs. two 1 mL injections in healthy participants.
The press release also reports the availability of Bimzelx Navigate for patients who have been prescribed Bimzelx. Bimzelx Navigate is a platform designed to support patients in their treatment journey. It provides each patient a dedicated “Nurse Navigator” who will discuss treatment goals, provide training on how to administer the medication, assist patients with financial guidance and update patients on the arrival of their medication.